Dermapharm stock sinks on mixed 1Q results

Published 15/05/2025, 09:30
Dermapharm stock sinks on mixed 1Q results

Investing.com -- Shares of Dermapharm Holding SE (ETR:DMPG) (ETR:DMP) tumbled 7.2% following the release of its first-quarter financial results, which presented a mixed picture of the company’s performance.

The German pharmaceutical company reported a slight revenue increase of 1% year-on-year (YoY) to €302.5 million, which was 2% higher than the consensus compiled by the company. However, investors seemed concerned with the decline in profitability, as adjusted EBITDA fell by 8% YoY to €81.3 million, with margins shrinking from 29.7% the previous year to 26.9%.

The branded pharmaceuticals segment showed resilience with a 2% YoY increase in revenue, reaching €146 million, and a 6% rise when excluding vaccine sales. However, this was overshadowed by a decrease in other healthcare products revenue by 3% YoY to €96.2 million. The parallel import business experienced a 7% YoY increase to €60.6 million, which was not enough to offset the overall negative sentiment.

The decline in profitability was more pronounced within the branded pharmaceuticals division, where margins contracted significantly from 49.8% to 45.3%. Other healthcare products also faced margin contraction, albeit less severe, from 18.7% to 18.1%. The parallel import business registered a negative margin of -1.5%, compared to a positive margin of 0.4% in the same quarter last year.

Operational cash flow plummeted to €4.2 million from €33.1 million in the prior-year period, and free cash flow (FCF) turned negative to -€5.1 million from a positive €26.4 million last year.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.